PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans”

The article, “How Blood-Plasma Companies Target the Poorest Americans,” by H. Luke Shaefer and Analidis Ochoa, published in The Atlantic on March 15, was unfair to plasma donors as well as to individuals living with rare, genetic, and chronic diseases who rely on access to plasma protein therapies. Plasma donors are due our gratitude and respect, not sweeping negative characterizations.

Regardless of their motivations, these donations save the lives of men, women, and children facing life-threatening diseases such as primary immunodeficiency, hemophilia, Alpha-1 antritrypsin, and hereditary angioedema.

The Plasma Protein Therapeutics Association’s primary focus is on regulatory and advocacy programs worldwide that support and enhance safety and access to plasma protein therapies for all those whose lives depend on them. As a trade association, we are prohibited from discussing or interfering in any individual company’s business practices. That said, PPTA thanks all plasma donors for their contribution to making life-saving medications for people all over the world. Without their commitment, those living with these diseases would go untreated.

On March 13, PPTA launched the global “How Is Your Day?” initiative, whose goals are to differentiate plasma protein therapies from traditional pharmaceuticals and show the value they provide to individuals who rely on access to these unique biologic medicines. As part of the initiative, plasma donors discuss why they are committed to providing their plasma, and patients share their stories and give thanks to donors worldwide.